Eligi
Med
Ensayos clinicos
Suscripcion
Sobre EligiMed
Ensayos Clinicos de Dermatologia | EligiMed
Ensayos clinicos
263 ensayos encontrados
Por invitacion
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Open-label, Single-arm, Extension Study to Evaluate the Long-term Safety and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy
INTERVENTIONAL
Inicio: 30 de jul de 2024
ID: NCT06475742
Completado
ClinicalTrials.gov
Assessment of Effectiveness of Dry Needling for Treating Shoulder Pain: a Randomized Controlled Trial
INTERVENTIONAL
Inicio: 1 de oct de 2018
ID: NCT05137106
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion
INTERVENTIONAL
Inicio: 2 de mar de 2021
ID: NCT04740905
Completado
Fase 3
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Safety and Efficacy of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines
INTERVENTIONAL
Inicio: 17 de oct de 2018
ID: NCT03580369
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-2
INTERVENTIONAL
Inicio: 1 de nov de 2015
ID: NCT02607618
Completado
Fase 3
ClinicalTrials.gov
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
INTERVENTIONAL
Inicio: 15 de mar de 2017
ID: NCT03136484
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-Day Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
INTERVENTIONAL
Inicio: 15 de ago de 2010
ID: NCT01170221
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
INTERVENTIONAL
Inicio: 24 de may de 2019
ID: NCT03952559
Completado
Fase 4
ClinicalTrials.gov
A 26 Week Randomised, Multinational, Open Labelled, 2 Armed, Parallel Group, Treat-to-target Once Daily Treatment Trial With Insulin Detemir Versus Insulin Glargine, Both in Combination With Metformin in Subjects With Type 2 Diabetes
INTERVENTIONAL
Inicio: 1 de may de 2009
ID: NCT00909480
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis
INTERVENTIONAL
Inicio: 27 de nov de 2017
ID: NCT03334422
Completado
Fase 2
ClinicalTrials.gov
A Double Blind, Randomized, Placebo Controlled, Multicenter, Dose Finding Study of Oral AEB071 Assessing Psoriasis Area and Severity Index (PASI) Response and a Function of Dose and Treatment Duration (Primary Outcome) in Patients With Plaque Psoriasis
INTERVENTIONAL
Inicio: 1 de abr de 2009
ID: NCT00885196
Completado
Fase 2
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy, Safety, and Tolerability of AMG 785 in Adults With a Fresh Unilateral Hip Fracture, Status Post Surgical Fixation
INTERVENTIONAL
Inicio: 20 de jun de 2010
ID: NCT01081678
Reclutando
Fase 2
ClinicalTrials.gov
Efectividad Del Plasma Rico en Plaquetas (PRP) Para la disminución Objetiva Del Dolor y la recuperación Funcional Del Miembro Inferior en Osteoartritis de Rodilla. Evaluación de Alternativas metodológicas
INTERVENTIONAL
Inicio: 1 de may de 2024
ID: NCT05825105
Reclutando
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
INTERVENTIONAL
Inicio: 23 de mar de 2021
ID: NCT04772079
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
INTERVENTIONAL
Inicio: 1 de jun de 2011
ID: NCT01358578
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
INTERVENTIONAL
Inicio: 12 de oct de 2022
ID: NCT05523167
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
INTERVENTIONAL
Inicio: 1 de may de 2012
ID: NCT01499277
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
INTERVENTIONAL
Inicio: 15 de abr de 2025
ID: NCT06934226
Desconocido
ClinicalTrials.gov
In Vivo Histology Evaluation of the CO2RE Device Versus the RePair Device in Pre- Abdominoplasty Patients
INTERVENTIONAL
Inicio: 1 de may de 2014
ID: NCT02147756
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant Intismeran Autogene (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007)
INTERVENTIONAL
Inicio: 18 de abr de 2024
ID: NCT06295809
Anterior
1
...
11
12
13
14
Siguiente
Filtros